Dr Reddy’s launches Hervycta to treat cancer in India
Team Udayavani, Jul 26, 2018, 12:00 PM IST
New Delhi: Drug major Dr Reddy’s Laboratories (DRL) today announced the launch of Hervycta, indicated for the treatment of certain types of cancer, in India.
Hervycta (Trastuzumab), a biosimilar of Roche’s Herceptin in India, is used for treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer).
Hervycta is available in strengths of 150 mg and 440 mg multiple dose vials, the company said in a regulatory filing.
“We strive every day to do what matters most for patients. Hervycta is a step forward in our effort to accelerate access to cancer patients in India, in the Oncology biosimilar space,” Dr Reddy’s Laboratories CEO-Branded Markets (India and Emerging Markets) MV Ramana said.
Quoting Ipsos data, the company said the Herceptin and its biosimilars had India sales of Rs 290 crore for the most recent 12 months ending in December 2017.
Dr Reddy’s currently has four biosimilar products commercialised in India and various emerging markets, and an active pipeline of several biosimilar products in the oncology and immunology space.
DRL shares were trading 1.01 per cent up at Rs 2,110 apiece on the BSE.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Mysuru double murder: Son brutally kills father, his lover
Six great India-Pakistan clashes in white-ball cricket
Was offered Rs 300-crore bribe to clear deals of ‘Ambani’, ‘RSS-linked man’: Ex-J&K Guv
Related Articles More
62.2% death row prisoners diagnosed with at least one mental illness: Study
Six popular beliefs about colds: experts explain the facts
Viral infections may promote Alzheimer’s like diseases: Study
COVID: new antibody treatment could offer up to 18 months’ protection against severe disease
COVID-19 and pregnancy: Women regret not getting the vaccine